Metformin for Abdominal Aortic Aneurysm Growth Inhibition
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 500 participants.
Also called NCT04224051
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 500 participants
- Sponsor
- Registry
-
NCT04224051
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Sweden
- Registry status
- Unknown status
Technical summary
Registry record NCT04224051. Randomized; no masking; primary purpose treatment. Start 2020-02-12 (actual); primary completion 2026-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Metformin for Abdominal Aortic Aneurysm Growth Inhibition
- Acronym
- MAAAGI
- Condition
- Abdominal Aortic Aneurysm
- Intervention (Drug)
- Metformin
- Intervention (Other)
- Standard care
- Lead sponsor
- Uppsala University Hospital
Record details
- Record id
cardio:ct-nct04224051- Content hash
bfac773fff484e7483942d6cb7d33efb81a202f4635b4e9f7ea271800269835c